Teva Pharmaceutical Industries Limited (NYSE: TEVA)’s stock price has plunge by 0.28relation to previous closing price of 10.56. Nevertheless, the company has seen a 10.08% surge in its stock price over the last five trading sessions. See It Market reported 2023-09-12 that Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick. This week, I covered TEVA, a stock I have talked about a few times and one, full disclosure, we are positioned in.
Is It Worth Investing in Teva Pharmaceutical Industries Limited (NYSE: TEVA) Right Now?
while the 36-month beta value is 1.17.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 2 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price point forecasted by analysts for Teva Pharmaceutical Industries Limited (TEVA) is $10.38, which is -$0.37 below the current market price. The public float for TEVA is 1.11B, and currently, short sellers hold a 1.52% ratio of that floaft. The average trading volume of TEVA on September 18, 2023 was 10.01M shares.
TEVA’s Market Performance
TEVA stock saw an increase of 10.08% in the past week, with a monthly gain of 12.42% and a quarterly increase of 39.71%. The volatility ratio for the week is 2.46%, and the volatility levels for the last 30 days are 2.16% for Teva Pharmaceutical Industries Limited (TEVA). The simple moving average for the past 20 days is 8.49% for TEVA’s stock, with a 17.63% simple moving average for the past 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with UBS repeating the rating for TEVA by listing it as a “Neutral.” The predicted price for TEVA in the upcoming period, according to UBS is $8 based on the research report published on July 06, 2023 of the current year 2023.
TEVA Trading at 15.63% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.47% of loss for the given period.
Volatility was left at 2.16%, however, over the last 30 days, the volatility rate increased by 2.46%, as shares surge +11.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.25% upper at present.
During the last 5 trading sessions, TEVA rose by +10.08%, which changed the moving average for the period of 200-days by +23.00% in comparison to the 20-day moving average, which settled at $9.81. In addition, Teva Pharmaceutical Industries Limited saw 16.12% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Kalif Eliyahu Sharon, who sale 35,125 shares at the price of $9.73 back on Aug 07. After this action, Kalif Eliyahu Sharon now owns 99,162 shares of Teva Pharmaceutical Industries Limited, valued at $341,889 using the latest closing price.
Weiss Amir, the Chief Accounting Officer of Teva Pharmaceutical Industries Limited, sale 1,981 shares at $9.92 during a trade that took place back on Aug 04, which means that Weiss Amir is holding 42,442 shares at $19,658 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- +17.96 for the present operating margin
- +46.68 for the gross margin
The net margin for Teva Pharmaceutical Industries Limited stands at -15.78. The total capital return value is set at 8.36, while invested capital returns managed to touch -8.02. Equity return is now at value -28.30, with -5.10 for asset returns.
Based on Teva Pharmaceutical Industries Limited (TEVA), the company’s capital structure generated 274.21 points at debt to equity in total, while total debt to capital is 73.28. Total debt to assets is 49.21, with long-term debt to equity ratio resting at 246.32. Finally, the long-term debt to capital ratio is 65.83.
When we switch over and look at the enterprise to sales, we see a ratio of 2.11, with the company’s debt to enterprise value settled at 0.72. The receivables turnover for the company is 3.69 and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.
Conclusion
In a nutshell, Teva Pharmaceutical Industries Limited (TEVA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
